These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21335031)

  • 1. Bioprocess optimization for cell culture based influenza vaccine production.
    Aggarwal K; Jing F; Maranga L; Liu J
    Vaccine; 2011 Apr; 29(17):3320-8. PubMed ID: 21335031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and strategies of cell-culture technology for influenza vaccine.
    Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M
    Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
    George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
    Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response.
    Seitz C; Isken B; Heynisch B; Rettkowski M; Frensing T; Reichl U
    Appl Microbiol Biotechnol; 2012 Jan; 93(2):601-11. PubMed ID: 21915610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells.
    Huang D; Xia-Hou K; Liu XP; Zhao L; Fan L; Ye Z; Tan WS; Luo J; Chen Z
    Vaccine; 2014 Dec; 32(52):7091-7. PubMed ID: 25444832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
    Doroshenko A; Halperin SA
    Expert Rev Vaccines; 2009 Jun; 8(6):679-88. PubMed ID: 19485748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
    Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
    Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
    Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Productivity, apoptosis, and infection dynamics of influenza A/PR/8 strains and A/PR/8-based reassortants.
    Isken B; Genzel Y; Reichl U
    Vaccine; 2012 Jul; 30(35):5253-61. PubMed ID: 22698452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAP, a new human suspension cell line for influenza virus production.
    Genzel Y; Behrendt I; Rödig J; Rapp E; Kueppers C; Kochanek S; Schiedner G; Reichl U
    Appl Microbiol Biotechnol; 2013 Jan; 97(1):111-22. PubMed ID: 22821436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.
    Hegde NR
    Hum Vaccin Immunother; 2015; 11(5):1223-34. PubMed ID: 25875691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine).
    Mabrouk T; Ellis RW
    Dev Biol (Basel); 2002; 110():125-34. PubMed ID: 12477315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles.
    Opitz L; Lehmann S; Reichl U; Wolff MW
    Biotechnol Bioeng; 2009 Aug; 103(6):1144-54. PubMed ID: 19449393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.
    Genzel Y; Olmer RM; Schäfer B; Reichl U
    Vaccine; 2006 Aug; 24(35-36):6074-87. PubMed ID: 16781022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming nutrient limitations for cell-based production of influenza vaccine.
    Liu XP; Huang D; Tan WS; Luo J; Chen Z
    Hum Vaccin Immunother; 2015; 11(7):1685-8. PubMed ID: 26061797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor.
    Trabelsi K; Rourou S; Loukil H; Majoul S; Kallel H
    J Biotechnol; 2006 Jan; 121(2):261-71. PubMed ID: 16153733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
    Genzel Y; Fischer M; Reichl U
    Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of MDCK cell culture-based influenza vaccines.
    Gregersen JP; Schmitt HJ; Trusheim H; Bröker M
    Future Microbiol; 2011 Feb; 6(2):143-52. PubMed ID: 21366415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.